Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders

Abstract Objectives To investigate the effect of either a booster vaccine (one dose) or revaccination (two doses 3 weeks apart) on the antibody response to the COVID-19 mRNA vaccines in patients with rheumatic disease (RD) treated with rituximab (RTX) who had not produced vaccine-reactive antibodies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Rheumatology (Oxford, England) England), 2023-07, Vol.62 (7), p.2544-2549
Hauptverfasser:	Ammitzbøll, Christian, Kragh Thomsen, Marianne, Bøgh Andersen, Jakob, Jensen, Jens Magnus Berth, From Hermansen, Marie-Louise, Dahl Johannsen, Anders, Larsen, Mads Lamm, Mistegaard, Clara Elbæk, Mikkelsen, Susan, Szabados, Fruzsina, Vils, Signe Risbøl, Erikstrup, Christian, Hauge, Ellen-Margrethe, Troldborg, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antibodies, Viral Antibody response Blood levels CD19 antigen CD45 antigen COVID-19 COVID-19 - prevention & control COVID-19 vaccines Flow cytometry Humans Immune response (humoral) Immunization, Secondary Immunotherapy Lymphocytes B Monoclonal antibodies mRNA mRNA vaccines Peripheral blood Rituximab Rituximab - therapeutic use SARS-CoV-2 Seroconversion Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccination Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!